HC Wainwright Issues Pessimistic Estimate for DRUG Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Stock analysts at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a report issued on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.73) per share for the quarter, down from their prior forecast of ($0.72). HC Wainwright has a “Buy” rating and a $85.00 price objective on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($2.30) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.79) EPS, FY2026 earnings at ($5.63) EPS, FY2027 earnings at ($5.72) EPS, FY2028 earnings at ($5.80) EPS and FY2029 earnings at ($1.70) EPS.

Bright Minds Biosciences (NASDAQ:DRUG) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.24.

DRUG has been the topic of a number of other research reports. Robert W. Baird assumed coverage on Bright Minds Biosciences in a report on Monday, November 25th. They issued an “outperform” rating and a $75.00 target price on the stock. Baird R W upgraded Bright Minds Biosciences to a “strong-buy” rating in a report on Monday, November 25th. Piper Sandler assumed coverage on Bright Minds Biosciences in a report on Thursday, January 23rd. They set an “overweight” rating and a $93.00 price target on the stock. Finally, Cantor Fitzgerald assumed coverage on Bright Minds Biosciences in a report on Friday, January 10th. They set an “overweight” rating on the stock. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $84.33.

Bright Minds Biosciences Trading Down 3.3 %

Shares of NASDAQ:DRUG opened at $36.15 on Friday. The business’s 50 day simple moving average is $38.08 and its two-hundred day simple moving average is $26.24. Bright Minds Biosciences has a 52-week low of $0.93 and a 52-week high of $79.02.

Institutional Trading of Bright Minds Biosciences

Large investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in Bright Minds Biosciences in the fourth quarter worth $238,000. Millennium Management LLC purchased a new stake in Bright Minds Biosciences in the fourth quarter worth $1,454,000. Point72 Asset Management L.P. purchased a new stake in Bright Minds Biosciences in the fourth quarter worth $4,870,000. Janus Henderson Group PLC purchased a new stake in Bright Minds Biosciences in the fourth quarter worth $18,392,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Bright Minds Biosciences in the fourth quarter worth $2,465,000. 40.52% of the stock is owned by hedge funds and other institutional investors.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.